SCHEMBL1838565

SCHEMBL1838565

c1ccc(Oc2ccccc2P(c2ccccc2)c2ccccc2Oc2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.44
LTA4H P09960 1/20 0.44
CYP3A4 P08684 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
RIPK1 Q13546 1/20 0.43
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42
HRH1 P35367 1/20 0.40
CTNNB1 P35222 1/20 0.40
ALDH1A1 P00352 2/20 0.39
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 2/20 0.39
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TLR4 O00206 1/20 0.39
TLR2 O60603 1/20 0.39
KDM1A O60341 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10976813 0.96 TSHR (0.44) TSHRLTA4HCYP3A4TDP1RIPK1
SCHEMBL1840257 0.89 LTA4H (0.50) TSHRLTA4HRIPK1LMNAGAA
SCHEMBL1840334 0.87 HTR2A (0.45) CYP3A4TDP1RIPK1LMNAKMT2A
SCHEMBL101880 0.85 CYP3A4 (0.50) TSHRLTA4HCYP3A4TDP1GAA
SCHEMBL16449662 0.83 CYP3A4 (0.41) TSHRLTA4HCYP3A4TDP1LMNA
SCHEMBL6714342 0.83 MAOB (0.56) CYP3A4RIPK1GAAKMT2AALDH1A1
SCHEMBL1836758 0.83 ALDH1A1 (0.39) TSHRLTA4HRIPK1LMNAKMT2A
SCHEMBL17674561 0.83 CYP3A4 (0.48) TSHRLTA4HCYP3A4TDP1GAA
SCHEMBL31153795 0.83 CYP3A4 (0.48) TSHRLTA4HCYP3A4TDP1GAA
SCHEMBL31059892 0.83 CYP3A4 (0.48) TSHRLTA4HCYP3A4TDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2321244-B1 IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES LLC (US) 2016-12-21 EP disclosed
US-8558030-B2 Process for telomerization of butadiene DOW GLOBAL TECHNOLOGIES LLC (US) 2013-10-15 US disclosed
US-20110137086-A1 PROCESS FOR TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (Formerly known as Dow Global Technologies Inc.) (US) 2011-06-09 US disclosed
EP-2321244-A2 AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (US) 2011-05-18 EP disclosed
WO-2010019360-A2 AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES INC. (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110137086-A1 PROCESS FOR TELOMERIZATION OF BUTADIENE HRH3, HRH4, TELO2 TSHR 1049/4885LTA4H 855/4885CYP3A4 1711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.